Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
REVIEW (Open Access)

The primary health care of transgender adults

Stuart Aitken
+ Author Affiliations
- Author Affiliations

Evandale Practice, 142 Bundall Road, Bundall, Qld 4217, Australia. Email: Drsaitken@gmail.com

Sexual Health 14(5) 477-483 https://doi.org/10.1071/SH17048
Submitted: 6 March 2017  Accepted: 11 April 2017   Published: 5 June 2017

Journal Compilation © CSIRO 2017 Open Access CC BY-NC-ND

Abstract

Gender dysphoria is associated with significant health disparity. Gender services perform specialised activities such as diagnosis, endocrine management and liaison with surgical services. Although providing these specialised transition services appears to be safe and improves well-being, significant health disparity remains. Engaging primary care providers is an important part of any strategy to improve the health care of transgender people. The relationships between gender dysphoria and a range of primary care issues such as mental health, cardiovascular disease and cancer are explored.


References

[1]  American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edn. Washington, DC: American Psychiatric Association; 2013.

[2]  Zucker KJ, Lawrence AA, Kreukels BPC. Gender dysphoria in adults. Annu Rev Clin Psychol 2016; 12 217–47.
Gender dysphoria in adults.CrossRef |

[3]  Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, De Cuypere G, Feldman J, Fraser L, Green J, Knudson G, Meyer WJ, Monstrey S, Adler RK, Brown GR, Devor AH, Ehrbar R, Ettner R, Eyler E, Garofalo R, Karasic DH, Lev AI, Mayer G, Meyer-Bahlburg H, Hall BP, Pfaefflin F, Rachlin K, Robinson B, Schechter LS, Tangpricha V, van Trotsenburg M, Vitale A, Winter S, Whittle S, Wylie KR, Zucker K. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism 2012; 13 165–232.
Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7.CrossRef |

[4]  Gorin-Lazard A, Baumstarck K, Boyer L, Maquigneau A, Gebieux S, Penochet JC, Pringuey D, Albarel F, Morange I, Loundou A, Berbis J, Auquier P, Lançon C, Bonierbale M. Is hormonal therapy associated with better quality of life in transsexuals? A cross-sectional study. J Sex Med 2012; 9 531–41.
Is hormonal therapy associated with better quality of life in transsexuals? A cross-sectional study.CrossRef |

[5]  Heylens G, Elaut E, Kreukels BP, Paap MC, Cerwenka S, Richter-Appelt H, Cohen-Kettenis PT, Haraldsen IR, De Cuypere G. Psychiatric characteristics in transsexual individuals: multicentre study in four European countries. Br J Psychiatry 2014; 204 151–6.
Psychiatric characteristics in transsexual individuals: multicentre study in four European countries.CrossRef |

[6]  Lawrence AA. Factors associated with satisfaction or regret following male to female sex reassignment surgery. Arch Sex Behav 2003; 32 299–315.
Factors associated with satisfaction or regret following male to female sex reassignment surgery.CrossRef |

[7]  Pfafflin F. Regrets after sex reassignment surgery. J Psychol Human Sex 1993; 5 69–85.
Regrets after sex reassignment surgery.CrossRef |

[8]  Dhejne C, Oberg K, Arver S, Landén M. An analysis of all applications for sex reassignment surgery in Sweden, 1960–2010: prevalence, incidence, regrets. Arch Sex Behav 2014; 43 1535–45.
An analysis of all applications for sex reassignment surgery in Sweden, 1960–2010: prevalence, incidence, regrets.CrossRef |

[9]  Spack NP. Management of transgenderism. JAMA 2013; 309 478–84.
Management of transgenderism.CrossRef |

[10]  Hembree W, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ, Spack NP, Tangpricha V, Montori VM, Endocrine Society Endocrine treatment of transsexual persons: an endocrine society practice guideline. J Clin Endocrinol Metab 2009; 94 3132–54.
Endocrine treatment of transsexual persons: an endocrine society practice guideline.CrossRef |

[11]  Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011; 164 635–42.
A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.CrossRef |

[12]  Asscheman H, T’Sjoen G, Lemaire A, Mas M, Meriggiola MC, Mueller A, Kuhn A, Dhejne C, Morel-Journel N, Gooren LJ. Venous thromboembolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review. Andrologia 2014; 46 791–5.
Venous thromboembolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review.CrossRef |

[13]  Meriggiola MC, Berra M. Safety of hormonal treatment in transgenders. Curr Opin Endocrinol Diabetes Obes 2013; 20 565–9.
Safety of hormonal treatment in transgenders.CrossRef |

[14]  Dhejne C, Lichtenstein P, Boman M, Johansson AL, Langstrom N, Landén M. Long-term follow up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden. PLoS One 2011; 6 e16885
Long-term follow up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden.CrossRef |

[15]  Reisner SL, Poteat T, Keatley J, Cabral M, Mothopeng T, Dunham E, Holland CE, Max R, Baral SD. Global health burden and needs of transgender populations: a review. Lancet 2016; 388 412–36.
Global health burden and needs of transgender populations: a review.CrossRef |

[16]  Colizzi M, Costa R, Pace V, Todarello O. Hormonal treatment reduces psychobiological distress in gender identity disorder, independently of the attachment style. J Sex Med 2013; 10 3049–58.
Hormonal treatment reduces psychobiological distress in gender identity disorder, independently of the attachment style.CrossRef |

[17]  Costantino A, Cerpolini S, Alvisi S, Morselli PG, Venturoli S, Meriggiola MC. A prospective study on sexual function and mood in female-to-male transsexuals during testosterone administration and after sex reassignment surgery. J Sex Marital Ther 2013; 39 321–35.
A prospective study on sexual function and mood in female-to-male transsexuals during testosterone administration and after sex reassignment surgery.CrossRef |

[18]  Balzer BW, Duke SA, Hawke CI, Steinbeck KS. The effects of estradiol on mood and behavior in human female adolescents: a systematic review. Eur J Pediatr 2015; 174 289–98.
The effects of estradiol on mood and behavior in human female adolescents: a systematic review.CrossRef |

[19]  Kranz GS, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, Haeusler D, Spies M, Mitterhauser M, Kasper S, Lanzenberger R. High-dose testosterone treatment increases serotonin transporter binding in transgender people. Biol Psychiatry 2015; 78 525–33.
High-dose testosterone treatment increases serotonin transporter binding in transgender people.CrossRef |

[20]  Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to male transsexuals: effects and risks of administration of androgens to females. J Sex Med 2008; 5 765–76.
Review of studies of androgen treatment of female-to male transsexuals: effects and risks of administration of androgens to females.CrossRef |

[21]  de Vries ALC, Noens ILJ, Cohen-Kettenis PT, van Berckelaer-Onnes IA, Doreleijers TA. Autism spectrum disorders in gender dysphoric children and adolescents. J Autism Dev Disord 2010; 40 930–6.
Autism spectrum disorders in gender dysphoric children and adolescents.CrossRef |

[22]  Glidden D, Bouman WP, Jones BA, Arcelus J. Gender dysphoria and autism spectrum disorders: a systematic review of the literature. Sex Med Rev 2016; 4 3–14.
Gender dysphoria and autism spectrum disorders: a systematic review of the literature.CrossRef |

[23]  Strang JF, Meagher H, Kenworthy L, de Vries ALC, Menvielle E, Leibowitz S, Janssen A, Cohen-Kettenis P, Shumer DE, Edwards-Leeper L, Pleak RR, Spack N, Karasic DH, Schreier H, Balleur A, Tishelman A, Ehrensaft D, Rodnan L, Kuschner ES, Mandel F, Caretto A, Lewis HC, Anthony LG. Initial clinical guidelines for co-occurring autism spectrum disorders and gender dysphoria or incongruence in adolescents. J Clin Child Adolesc Psychol 2017; in press
Initial clinical guidelines for co-occurring autism spectrum disorders and gender dysphoria or incongruence in adolescents.CrossRef |

[24]  Elamin MB, Garcia MZ, Murad MH, Erwin PJ, Montori VM. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analysis. Clin Endocrinol 2010; 72 1–10.
Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analysis.CrossRef |

[25]  van Kesteren PJM, Asscheman H, Megens JAJ, Gooren LJG. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol 1997; 47 337–43.
Mortality and morbidity in transsexual subjects treated with cross-sex hormones.CrossRef |

[26]  Gooren LJ, Wierckx K, Giltay EJ. Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex differences in cardiovascular disease pattern. Eur J Endocrinol 2014; 170 809–19.
Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex differences in cardiovascular disease pattern.CrossRef |

[27]  Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17betaestradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception 2013; 87 706–27.
Ethinyl estradiol and 17betaestradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment.CrossRef |

[28]  Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, T’Sjoen G. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med 2012; 9 2641–51.
Long-term evaluation of cross-sex hormone treatment in transsexual persons.CrossRef |

[29]  Mueller A, Zollver H, Kronawitter D, Oppelt PG, Claassen T, Hoffmann I, Beckmann MW, Dittrich R. Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 2011; 119 95–100.
Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist.CrossRef |

[30]  Van Caenegem E, Wierckx K, Taes Y, Dedecker D, Van de Peer F, Toye K, Kaufman JM, T’Sjoen G. Bone mass, bone geometry and body composition in female to male transsexual persons after long term cross-sex hormone therapy. J Clin Endocrinol Metab 2012; 97 2503–11.
Bone mass, bone geometry and body composition in female to male transsexual persons after long term cross-sex hormone therapy.CrossRef |

[31]  Seal LJ. A review of the physical and metabolic effects of cross-sex hormonal therapy in the treatment of gender dysphoria. Ann Clin Biochem 2016; 53 10–20.
A review of the physical and metabolic effects of cross-sex hormonal therapy in the treatment of gender dysphoria.CrossRef |

[32]  Cupisti S, Giltay EJ, Gooren LJ, Kronawitter D, Oppelt PG, Beckmann MW, Dittrich R, Mueller A. The impact of testosterone administration to female-to-male transsexuals on insulin resistance and lipid parameters compared with women with polycystic ovary syndrome. Fertil Steril 2010; 94 2647–53.
The impact of testosterone administration to female-to-male transsexuals on insulin resistance and lipid parameters compared with women with polycystic ovary syndrome.CrossRef |

[33]  Feldman J. Preventive care of the transgender patient: an evidence-based approach. In Ettner R, Monstrey S, Coleman E, editors. Principals of transgender medicine and surgery, 2nd edn. New York: Routledge; 2016. pp. 100–20.

[34]  Hokken-Koelega A, van der Lely AJ, Hauffa B, Häusler G, Johannsson G, Maghnie M, Argente J, DeSchepper J, Gleeson H, Gregory JW, Höybye C, Keleştimur F, Luger A, Müller HL, Neggers S, Popovic-Brkic V, Porcu E, Sävendahl L, Shalet S, Spiliotis B, Tauber M. Bridging the gap: metabolic and endocrine care of patients during transition. Endocr Connect 2016; 5 R44–54.
Bridging the gap: metabolic and endocrine care of patients during transition.CrossRef |

[35]  Gardner IH, Safer JD. Progress on the road to better medical care for transgender patients. Curr Opin Endocrinol Diabetes Obes 2013; 20 553–8.
Progress on the road to better medical care for transgender patients.CrossRef |

[36]  Ott J, Kaufmann U, Bentz EK, Huber JC, Tempfer CB. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertil Steril 2010; 93 1267–72.
Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy.CrossRef |

[37]  Shatzel JJ, Connelly KJ, DeLoughery TG. Thrombotic issues in transgender medicine: a review. Am J Hematol 2017; 92 204–8.
Thrombotic issues in transgender medicine: a review.CrossRef |

[38]  Roberts TK, Kraft CS, French D, Ji W, Tangpricha V, Fantz CR. Interpreting laboratory results in transgender patients on hormone therapy. Am J Med 2014; 127 159–62.
Interpreting laboratory results in transgender patients on hormone therapy.CrossRef |

[39]  Jones RA, Schultz CG, Chatterton BE. A longitudinal study of bone mineral density in reassigned transsexuals. Bone 2009; 44 S126
A longitudinal study of bone mineral density in reassigned transsexuals.CrossRef |

[40]  T’Sjoen G, Weyers S, Taes Y, Lapauw B, Toye K, Goemaere S, Kaufman JM. Prevalence of low bone mass in relation to estrogen treatment and body composition in male-to-female transsexual persons. J Clin Densitom 2009; 12 306–13.
Prevalence of low bone mass in relation to estrogen treatment and body composition in male-to-female transsexual persons.CrossRef |

[41]  Traish AM, Gooren LJ. Safety of physiological testosterone therapy in women: lessons from female-to-male transsexuals (FMT) treated with pharmacological testosterone therapy. J Sex Med 2010; 7 3758–64.
Safety of physiological testosterone therapy in women: lessons from female-to-male transsexuals (FMT) treated with pharmacological testosterone therapy.CrossRef |

[42]  Vlot MC, Klink DT, den Heijer M, Blankenstein MA, Rotteveel J, Heijboer AC. Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents. Bone 2017; 95 11–9.
Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents.CrossRef |

[43]  Costa R, Carmichael P, Colizzi M. To treat or not to treat: puberty suppression in childhood-onset gender dysphoria. Nat Rev Urol 2016; 13 456–62.
To treat or not to treat: puberty suppression in childhood-onset gender dysphoria.CrossRef |

[44]  Park HK, Lee HS, Jo JH, Hwang IT, Lim JS, Hwang JS. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with precocious puberty. Clin Endocrinol 2012; 77 743
The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with precocious puberty.CrossRef |

[45]  Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotrophin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content and reproductive function. J Clin Endocrinol Metab 2008; 93 190–5.
Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotrophin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content and reproductive function.CrossRef |

[46]  American College of Obstetrics and Gynecology. Committee opinion: health care for transgender individuals. Available online at: http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Health-Care-for-Underserved-Women/Health-Care-for-Transgender-Individuals [verified 28 February 2017].

[47]  Peitzmeier SM, Khullar K, Reisner SL, Potter J. Pap test use is lower among female-to-male patients than non-transgender women. Am J Prev Med 2014; 47 808–12.
Pap test use is lower among female-to-male patients than non-transgender women.CrossRef |

[48]  Peitzmeier SM, Reisner SL, Harigopal P, Potter J. Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical screening. J Gen Intern Med 2014; 29 778–84.
Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical screening.CrossRef |

[49]  Smith M, Lew JB, Simms K, Canfell K. Impact of HPV sample self-collection for under-screened women in the renewed cervical screening program. Med J Aust 2016; 204 194
Impact of HPV sample self-collection for under-screened women in the renewed cervical screening program.CrossRef |

[50]  Spinder T, Spijkstra JJ, van den Tweel JG, Burger CW, van Kessel H, Hompes PG, Gooren LJ. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects. J Clin Endocrinol Metab 1989; 97 2503–11.

[51]  Urban RR, Teng NNH, Kapp DS. Gynecologic malignancies in female-to-male transgender patients: the need for original gender surveillance. Am J Obstet Gynecol 2011; 204 e9–12.
Gynecologic malignancies in female-to-male transgender patients: the need for original gender surveillance.CrossRef |

[52]  Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, De Giorgi LB, Formelli G, Casadio P, Ghi T, Pelusi G, Pelusi C, Meriggiola MC. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med 2009; 6 3193–200.
Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals.CrossRef |

[53]  Grynberg M, Fanchin R, Dubost G, Colau J-C, Brémont-Weil C, Frydman R, Ayoubi JM. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online 2010; 20 553–8.
Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population.CrossRef |

[54]  Mueller A, Gooren L. Hormone-related tumours in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2008; 159 197–202.
Hormone-related tumours in transsexuals receiving treatment with cross-sex hormones.CrossRef |

[55]  Slagter MH, Gooren L, Scorilas A, Petraki CD, Diamandis EP. Effects of long-term androgen administration on breast tissue of female to male transsexuals. J Histochem Cytochem 2006; 54 905–10.
Effects of long-term androgen administration on breast tissue of female to male transsexuals.CrossRef |

[56]  Fryzek JP, Ye W, Nyrén O, Tarone RE, Lipworth L, McLaughlin JK. A nationwide epidemiological study of breast cancer incidence following breast reduction surgery in a large cohort of Swedish women. Breast Cancer Res Treat 2006; 97 131–4.
A nationwide epidemiological study of breast cancer incidence following breast reduction surgery in a large cohort of Swedish women.CrossRef |

[57]  Gooren LJ. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med 2013; 10 3129–34.
Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.CrossRef |

[58]  Wilson JD, Roehrborn C. Long-term consequences of castration in men: lessons from the Skoptzky and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab 1999; 84 4324–31.
Long-term consequences of castration in men: lessons from the Skoptzky and the eunuchs of the Chinese and Ottoman courts.CrossRef |

[59]  Morgentaler A. Goodbye androgen hypothesis, hello saturation model. Eur Urol 2012; 62 765–7.
Goodbye androgen hypothesis, hello saturation model.CrossRef |

[60]  Gooren LJ, Morgentaler A. Prostate cancer incidence in orchidectomised male-to female transsexual persons treated with oestrogens. Andrologia 2014; 46 1156–60.
Prostate cancer incidence in orchidectomised male-to female transsexual persons treated with oestrogens.CrossRef |

[61]  Gooren LJ, Giltay EJ, Bunck MC. Long-term care of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008; 93 19–25.
Long-term care of transsexuals with cross-sex hormones: extensive personal experience.CrossRef |

[62]  Bunck MC, Debono M, Giltay EJ, Verheijen AT, Diamant M, Gooren LJ. Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen doses. BMJ Case Reports 2009;
Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen doses.CrossRef |

[63]  Cunha FS, Domenice S, Câmara VL, Sircli MH, Gooren LJ, Mendonça BB, Costa EM. Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy. Andrologia 2015; 47 680–4.
Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy.CrossRef |

[64]  Gray E. The transgender tipping point. Time 2014; 9 Available online at: http://time.com/135480/transgender-tippingpoint/ [verified 28 February 2017].

[65]  United Nations. Report of the United Nations High Commissioner for Human Rights, discriminatory laws and practices and acts of violence against individuals based on their sexual orientation and gender identity, A/HRC/19/41. Geneva: United Nations; 2011.

[66]  Quinn GP, Sanchez JA, Sutton SK, Vadaparampil ST, Nguyen GT, Green BL, Kanetsky PA, Schabath MB. Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning populations (LGBTQ). CA Cancer J Clin 2015; 65 384–400.
Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning populations (LGBTQ).CrossRef |

[67]  Shindel AW, Baazeem A, Eardly I, Coleman E. Sexual health in undergraduate medical education: existing and future needs and platforms. J Sex Med 2016; 13 1013–26.
Sexual health in undergraduate medical education: existing and future needs and platforms.CrossRef |

[68]  Obedin-Maliver J, Goldsmith ES, Stewart L, White W, Tran E. Lesbian, gay, bisexual, and transgender-related content in undergraduate medical education. JAMA 2011; 3306 971–7.

[69]  Dy GW, Osbun NC, Morrison SD, Grant DW, Merguerian PA, Transgender Education Study Group Exposure to and attitudes regarding transgender education among urology residents. J Sex Med 2016; 13 1466–72.
Exposure to and attitudes regarding transgender education among urology residents.CrossRef |

[70]  Vanderleest JG, Galper CQ. Improving the health of transgender people: transgender medical education in Arizona. J Assoc Nurses AIDS Care 2009; 20 411–6.
Improving the health of transgender people: transgender medical education in Arizona.CrossRef |

[71]  Kidd JD, Bockting W, Cabaniss DL, Bumenshine P. Special-“T” training: extended follow-up results from a residency-wide professionalism workshop in transgender health. Acad Psychiatry 2016; 40 802–6.
Special-“T” training: extended follow-up results from a residency-wide professionalism workshop in transgender health.CrossRef |

[72]  UCSF Centre of Excellence in Transgender Health. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people. Available online at: http://transhealth.ucsf.edu/trans?page=guidelines-clinic-environment [verified 28 February 2017].


Full Text PDF (162 KB) Export Citation Cited By (1)

View Altmetrics